Controlled release fumarate esters
View Patent ↗Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release fumarate esters are described.
1. A method for treating or reducing symptoms of multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a pharmaceutical composition comprising one or more fumarate esters suspended a matrix comprising a lipid or lipophilic vehicle at a weight ratio of fumarate ester to matrix from about 1:1 to about 1:5, wherein the lipid or lipophilic vehicle comprises a mixture of mono- and di-glycerides, polyvinylpyrrolidone, and polyoxyl 40 hydrogenated castor oil.
2. The method of claim 1 , wherein the fumarate ester comprises dimethyl fumarate, monomethyl fumarate, or a combination thereof.
3. The method of claim 1 , wherein the fumarate ester comprises dimethyl fumarate.
4. The method of claim 1 , wherein the fumarate ester comprises monomethyl fumarate.
5. The method of claim 1 , wherein the matrix further comprises lactic acid.
6. The method of claim 1 , wherein the pharmaceutical composition comprises:
about 25% to about 50% of one or more fumarate esters;
about 40% to about 54% of a mixture of mono- and di-glycerides;
about 1% to about 10% polyvinylpyrrolidone; and
about 2% to about 10% polyoxyl 40 hydrogenated castor oil.
7. The method of claim 6 , wherein the pharmaceutical composition further comprises about 1% to about 5% lactic acid.
8. The method of claim 1 , wherein the pharmaceutical composition comprises:
about 28% of one or more fumarate esters;
about 54% of a mixture of mono- and di-glycerides;
about 3% polyvinylpyrrolidone; and
about 10% polyoxyl 40 hydrogenated castor oil.
9. The method of claim 8 , wherein the pharmaceutical composition further comprises about 5% lactic acid.
10. The method of claim 1 , wherein the pharmaceutical composition has controlled release properties.
11. The method of claim 1 , wherein the pharmaceutical composition reduces gastrointestinal or flushing side effects.
12. The method of claim 1 , wherein the pharmaceutical composition is encapsulated in a soft capsule.
13. The method of claim 1 , wherein the pharmaceutical composition is encapsulated in an enteric soft capsule.
14. A method for treating or reducing symptoms of a multiple sclerosis or psoriasis comprising orally administering to a subject in need thereof a pharmaceutical composition comprising:
about 25% to about 50% of one or more fumarate esters comprising dimethyl fumarate, monomethyl fumarate, or a combination thereof;
about 40% to about 54% of a mixture of mono- and di-glycerides;
about 1% to about 10% polyvinylpyrrolidone; and
about 2% to about 10% polyoxyl 40 hydrogenated castor oil.
15. The method of claim 14 , wherein the pharmaceutical composition further comprises about 1% to about 5% lactic acid.
16. The method of claim 14 , wherein the fumarate ester comprises dimethyl fumarate.
17. The method of claim 14 , wherein the fumarate ester comprises monomethyl fumarate.
18. The method of claim 14 , wherein the pharmaceutical composition has controlled release properties.
19. The method of claim 14 , wherein the pharmaceutical composition reduces gastrointestinal or flushing side effects.
20. The method of claim 14 , wherein the pharmaceutical composition is encapsulated in a soft capsule.
21. A method for treating or reducing symptoms of multiple sclerosis or psoriasis comprising orally administering to a subject in need thereof a pharmaceutical composition comprising:
about 25% to about 50% of one or more fumarate esters comprising dimethyl fumarate, monomethyl fumarate, or a combination thereof; and
about 50% to about 75% of a lipid or lipophilic vehicle, wherein the lipid or lipophilic vehicle comprises a mixture of mono- and di-glycerides, polyvinylpyrrolidone, and polyoxyl 40 hydrogenated castor oil.
22. The method of claim 21 , wherein the pharmaceutical composition further comprises about 1% to about 5% lactic acid.
23. The method of claim 21 , wherein the fumarate ester comprises dimethyl fumarate.
24. The method of claim 21 , wherein the fumarate ester comprises monomethyl fumarate.
25. The method of claim 21 , wherein the pharmaceutical composition has controlled release properties.
26. The method of claim 21 , wherein the pharmaceutical composition reduces gastrointestinal or flushing side effects.
27. The method of claim 21 , wherein the pharmaceutical composition is encapsulated in a soft capsule.